86 related articles for article (PubMed ID: 23264214)
1. E-cadherin expression is more associated with histopathological type of thyroid cancer than with the metastatic potential of tumors.
Slowinska-Klencka D; Sporny S; Stasikowska-Kanicka O; Popowicz B; Klencki M
Folia Histochem Cytobiol; 2012; 50(4):519-26. PubMed ID: 23264214
[TBL] [Abstract][Full Text] [Related]
2. [Expression of EpCAM and E-cadherin in papillary thyroid carcinoma and its clinicopathologic significance].
Cheng Y; Meng Y; Liang Z; Yang C; Luo Y; Cui Q
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):189-94. PubMed ID: 26268754
[TBL] [Abstract][Full Text] [Related]
3. The expression of CK19, vimentin and E-cadherin in differentiated thyroid carcinomas.
Calangiu CM; Simionescu CE; Stepan AE; Cernea D; Zăvoi RE; Mărgăritescu C
Rom J Morphol Embryol; 2014; 55(3):919-25. PubMed ID: 25329121
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of E-cadherin expression in thyroid neoplasms.
Naito A; Iwase H; Kuzushima T; Nakamura T; Kobayashi S
J Surg Oncol; 2001 Mar; 76(3):176-80. PubMed ID: 11276021
[TBL] [Abstract][Full Text] [Related]
6. Dysadherin: expression and clinical significance in thyroid carcinoma.
Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
[TBL] [Abstract][Full Text] [Related]
7. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma.
Erdem H; Gündogdu C; Sipal S
Exp Mol Pathol; 2011 Jun; 90(3):312-7. PubMed ID: 21335003
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin: a differentiation marker in thyroid malignancies.
Brabant G; Hoang-Vu C; Cetin Y; Dralle H; Scheumann G; Mölne J; Hansson G; Jansson S; Ericson LE; Nilsson M
Cancer Res; 1993 Oct; 53(20):4987-93. PubMed ID: 8402689
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas.
Scheumman GF; Hoang-Vu C; Cetin Y; Gimm O; Behrends J; von Wasielewski R; Georgii A; Birchmeier W; von Zur Mühlen A; Dralle H
J Clin Endocrinol Metab; 1995 Jul; 80(7):2168-72. PubMed ID: 7608273
[TBL] [Abstract][Full Text] [Related]
10. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
11. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
12. [Expression of E-cadherin in thyroid neoplastic tissues and its correlation with malignant and metastatic potential].
Naitoh A; Kobayashi S; Iwase H; Kuzushima T
Nihon Rinsho; 1995 Jul; 53(7):1619-22. PubMed ID: 7629998
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer.
Yamamoto S; Tomita Y; Uruno T; Hoshida Y; Qiu Y; Iizuka N; Nakamichi I; Miyauchi A; Aozasa K
Ann Surg Oncol; 2005 Nov; 12(11):925-34. PubMed ID: 16189643
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
15. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
16. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin gene alterations are rare events in thyroid tumors.
Soares P; Berx G; van Roy F; Sobrinho-Simões M
Int J Cancer; 1997 Jan; 70(1):32-8. PubMed ID: 8985087
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of E-cadherin expression in thyroid follicular carcinoma.
Brecelj E; Frković Grazio S; Auersperg M; Bracko M
Eur J Surg Oncol; 2005 Jun; 31(5):544-8. PubMed ID: 15922891
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
20. [Expression of the selected adhesive molecules (cadherin E, CD44, LGAL3 and CA50) in papillary thyroid carcinoma].
Nikiel B; Chekan M; Jaworska M; Jarzab M; Maksymiuk B; Lange D
Endokrynol Pol; 2006; 57(4):326-35. PubMed ID: 17006832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
